Seres Therapeutics, Inc. Dividend History (MCRB)

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a cutting-edge biotechnology company founded in 2010 by Noubar Afeyan, David Berry, and Simeon George. Headquartered in Cambridge, Massachusetts, Seres is pioneering the development of microbiome therapeutics, which aim to harness the body's natural microbial communities to treat various diseases. The company's most notable work includes SER-109, an investigational therapeutic designed to reduce the recurrence of Clostridioides difficile infection, a significant cause of infectious disease deaths in the U.S. As a publicly traded company on the NASDAQ under the ticker MCRB, Seres Therapeutics is dedicated to transforming medical treatment by understanding and utilizing the microbiome's pivotal role in human health. The company has been active in advancing microbiome science and partners with industry leaders like Nestlé Health Science to further the commercialization of its breakthrough therapies.